Keywords: Merck KGaA, Cladribine, Multiple sclerosis, Novartis, Gilenya

Merck KGaA drops plans for oral MS drug cladribine, leaving field clear for Gilenya

Article | 23 June 2011

Print This

German drug major Merck KGaA (MRK: DE) said yesterday that, following feedback from regulatory authorities, the company has decided to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in